Navigation Links
Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia
Date:8/12/2009

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck/Schering-Plough's Zetia and Vytorin have lost substantial patient share in second- and third-line therapy since last year's analysis of the dyslipidemia drug market. This decline is most likely attributed to the publication of the ENHANCE trial which called into question the ability of these agents to improve clinical outcomes beyond the ability of statin monotherapy.

The new Treatment Algorithms in Dyslipidemia report also finds that statins have gained patient share with Zetia's and Vytorin's decline in use since the ENHANCE fallout. Survey results indicate that over the next two years cardiologists and primary care physicians intend to be more aggressive in their treatment of dyslipidemia. They also plan to increase their use of the most potent statins, particularly Pfizer's Lipitor and AstraZeneca's Crestor, and adjunct agents belonging to the classes of fenofibrates and bile acid sequestrants.

"Our survey of physicians indicates that favorable results from the 2008 JUPITER trial are likely to increase the percentage of physicians prescribing Crestor in the first line and may lead to increases in Crestor's patient share. However, Crestor will have to compete with the availability of generic Lipitor in 2011 and AstraZeneca should try to gain as much traction as possible prior to the arrival of this additional competition," stated Amanda Puffer, M.Sc., analyst at Decision Resources.

By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.

'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HCM Announces Substantial Growth in 2007
2. Excalibur Celebrates PIramed Sale With Substantial Cash Return to Investors
3. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
4. KJT Group Positions for Substantial Growth
5. Gerresheimer Substantially Increases Quarterly Operating Profit
6. Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
7. Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers Disease
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Grade school history lessons often have it that American ... whooping cough, chicken pox, influenza and tuberculosis brought to ... while estimates vary, about 20 million people lived in ... percent of them were killed by European diseases., But ... Arizona State University and Johannes Krause of the University ...
(Date:8/20/2014)... 20, 2014  PAREXEL International Corporation (NASDAQ: ... at the Baird Healthcare Conference in New York.  ... Officer, will be making a presentation on PAREXEL and ... Sept. 3, 2014. A live webcast of ... of PAREXEL,s website at www.PAREXEL.com in the ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... -- A Geisinger researcher on a personal crusade against ... Disease Control and Prevention (CDC) award recognizing his unprecedented ... Joseph Boscarino , Ph.D. MPH, senior scientist, ... researchers nominated for the Centers for Disease Control and ... Methods and Study Design. "Hepatitis C killed ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3PAREXEL International To Present At Baird Healthcare Conference 2EQ-5D™ Assessment Now Available for iPad 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... January 24 The European Commission has granted,marketing ... antidepressant for the treatment of adult patients,with major ... is still great scope for improved therapies to ... from Warneford,Hospital, Oxford, United Kingdom. "Valdoxan is an ...
... has launched www.EyeScience.com to fill a large ... macular degeneration (AMD) in a unique watch-and-learn video format. ... the leading cause of blindness in Americans age 50 ... basic eye anatomy, screening and diagnosis, risk factors, signs ...
... Feb. 24 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading ... the People,s Republic of China ("PRC"), today ... Jin Chuang Pharmaceutical Company ("Jin,Chuang"), signed an ...
Cached Biology Technology:Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 2Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 3EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 3
(Date:8/21/2014)... New feeding tube connectors, designed by an international standards ... safety. , According to an invited review published in ... ( NCP ), the official journal of the ... new connectors will greatly reduce the occurrence of misconnection ... , Small-bore connectors, which are used to join medical ...
(Date:8/21/2014)... RUSTON, La. A team of researchers ... innovative method for using affordable, consumer-grade 3D ... implants that can contain antibacterial and chemotherapeutic ... team comprised of doctoral students and research ... nanosystems engineering programs collaborated to create filament ...
(Date:8/21/2014)... An Australian National University (ANU) team has successfully replicated ... way for biological systems powered by sunlight which could ... and so is sunlight. It is an exciting prospect ... cheaply and safely," said Dr Kastoori Hingorani, from the ... ANU Research School of Biology. , Hydrogen offers potential ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Water and sunlight the formula for sustainable fuel 2
... of frozen methane deposits is the likely cause of a ... years ago, according to an international research team led by ... finding is expected to come as a relief to scientists ... might have been touched off by methane melts in the ...
... individuals around the world are alive because of him. ... to make the use of life-saving devices such as ... and heart-lung bypass systems almost commonplace. In the ... biomaterials leader. John Brash, P.Eng., director of the ...
... in preparing for how data from the Sentinel-1 European ... land-cover mapping and crop management. Sentinel-1 is the first ... the GMES initiative. Sentinel-1 is a constellation of ... day and night imagery for use in a range ...
Cached Biology News:Wetlands likely source of methane from ancient warming event 2Wetlands likely source of methane from ancient warming event 3Canadian biomedical engineering pioneer receives international award 2A glimpse of future GMES Sentinel-1 radar images 2
... contains choice of PDMS Stamps (3 PDMS ... 200 micron squares or 100 um x ... mm lines, 3 PDMS nano-patterned stamps with ... and pitch of 400 nm, or 3 ...
...
... The product contains 5 ml of DETACHaBEAD ... release mouse CD4+ T cells from Dynabeads ... mosue CD4+ T cells from Dynabeads Mouse ... cells are suitable for any downstream application ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: